胸腔镜治疗胸腺瘤的安全性及中长期疗效分析

发布时间：2018-11-02 17:01

【摘要】：目的探讨胸腔镜治疗胸腺瘤的安全性及中长期疗效。方法回顾性分析2001年4月~2014年11月我科胸腔镜治疗胸腺瘤185例资料,并随访生存和复发情况。结果中转开胸7例(3.8%),主要中转开胸原因为肿瘤侵犯大血管(5例)。MasaokaⅠ期123例(66.5%),Ⅱ期37例(20.0%),Ⅲ期19例(10.3%),Ⅳ期6例(3.2%)。MasaokaⅠ、Ⅱ、Ⅲ、Ⅳ期的R0切除率分别为100%(123/123)、100%(37/37)、89.5%(17/19)、66.7%(4/6)。手术时间(136.5±51.6)min,中位出血量50 ml(10~2500 ml),术后带管时间(3.2±1.8)d,术后住院时间(5.8±2.9)d。全组无围手术期死亡,术后并发症10例(5.4%)。随访167例(90.3%),中位随访时间44个月(3~174个月)。5年总生存率94.6%,10年总生存率89.3%。合并重症肌无力45例中成功随访41例,完全缓解9例,部分缓解23例,总体缓解率78.0%(32/41)。结论胸腔镜治疗早期(MasaokaⅠ、Ⅱ期)及部分经过选择的晚期(MasaokaⅢ、Ⅳ期)胸腺瘤安全有效,且长期疗效满意。胸腔镜胸腺扩大切除治疗胸腺瘤合并重症肌无力疗效满意。
[Abstract]:Objective to investigate the safety and long-term efficacy of thoracoscopy in the treatment of thymoma. Methods 185 cases of thymoma treated by thoracoscopy from April 2001 to November 2014 were retrospectively analyzed and their survival and recurrence were followed up. Results 7 cases (3.8%) were converted to thoracotomy. The main causes of conversion were tumor invasion of large vessels (123 cases (66.5%) in 5 cases of). Masaoka 鈪，

本文编号：2306403